1-7 of 7
Susan D. Demo, PhD
Close
Sort by
Journal Articles

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Deborah J. Kuhn, PhD, Qing Chen, PhD, Peter M. Voorhees, MD, John S. Strader, Kevin D. Shenk, PhD, Congcong M. Sun, PhD, Susan D. Demo, PhD, Mark K. Bennett, PhD, Fred W. van Leeuwen, PhD, Robert Z. Orlowski, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 3461.
https://doi.org/10.1182/blood.V108.11.3461.3461
Published: 2006
Journal Articles

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity.

Susan D. Demo, PhD, Monette A. Aujay, BS, Eileen Goldstein, BS, Guy J. Laidig, PhD, Francesco Parlati, PhD, Yan Lu, PhD, Kevin D. Shenk, BS, Congcong M. Sun, MS, Catherine Sylvain, PhD, Tina M. Woo, BS, Hanjie Zhou, PhD, Mark K. Bennett, PhD
Journal: Blood
Blood (2006) 108 (11): 4398.
https://doi.org/10.1182/blood.V108.11.4398.4398
Published: 2006
Journal Articles

A Proteasome Specific Binding Assay for Quantitation of Constitutive and Immunoproteasome Active Sites.

Mark K. Bennett, PhD, Monette A. Aujay, BS, Tonia J. Buchholz, MS, Susan D. Demo, PhD, Guy J. Laidig, PhD, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina Woo, BS, Mark S. Smyth, PhD
Journal: Blood
Blood (2005) 106 (11): 2472.
https://doi.org/10.1182/blood.V106.11.2472.2472
Published: 2005
Journal Articles

Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome.

Christopher J. Kirk, PhD, Mark K. Bennett, PhD, Tonia J. Buchholz, MS, Susan D. Demo, PhD, Mark N. Ho, BS, Jing Jiang, BS, Guy J. Laidig, PhD, Evan R. Lewis, PhD, Kevin D. Shenk, BS, Mark S. Smyth, PhD, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina M. Woo, BS, Christopher J. Molineaux, PhD
Journal: Blood
Blood (2005) 106 (11): 609.
https://doi.org/10.1182/blood.V106.11.609.609
Published: 2005
Journal Articles

The Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma Cells.

Douglas Ivancsits, Rama Nimmanapali, PhD, Megan Sun, Kevin Shenk, Susan D. Demo, PhD, Mark K. Bennett, PhD, William S. Dalton, MD, PhD, Melissa Alsina, MD
Journal: Blood
Blood (2005) 106 (11): 1575.
https://doi.org/10.1182/blood.V106.11.1575.1575
Published: 2005
Journal Articles

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.

Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, John S. Strader, PA, Kevin D. Shenk, PhD, Congcong M. Sun, PhD, Susan D. Demo, PhD, Mark K. Bennett, PhD, Robert Z. Orlowski, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 1576.
https://doi.org/10.1182/blood.V106.11.1576.1576
Published: 2005
Journal Articles

Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171.

Susan D. Demo, PhD, Tonia J. Buchholz, MS, Guy J. Laidig, PhD, Francesco Parlati, PhD, Kevin D. Shenk, BS, Mark S. Smyth, PhD, Carol M. Sullivan, BA, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina Woo, BS, Mark K. Bennett, PhD
Journal: Blood
Blood (2005) 106 (11): 1588.
https://doi.org/10.1182/blood.V106.11.1588.1588
Published: 2005